<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2577">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593654</url>
  </required_header>
  <id_info>
    <org_study_id>Thromboprophylaxis COVID-19</org_study_id>
    <nct_id>NCT04593654</nct_id>
  </id_info>
  <brief_title>Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients</brief_title>
  <official_title>Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients - More Patients Included and 90-day Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to associate dose of thromboprophylaxis with outcome in critically&#xD;
      ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with&#xD;
      28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This&#xD;
      was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov&#xD;
      NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half&#xD;
      of July and we will ad the outcome of 90-day mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days from ICU-admission</time_frame>
    <description>28-day mortality from admission to ICU. Discontinue of ICU-care to palliative care counts as death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic events</measure>
    <time_frame>28 days from ICU-admission</time_frame>
    <description>Thromboembolic events are defined as pulmonary emboli (PE), deep venous thrombus (DVT) and ischemic stroke. PE is defined as PE verified by computer tomography or by findings of acute strain of the right heart on echocardiography combined with a clinical interpretation of the patients deteriorating as a probable PE stated in the medical records. DVT is defined as DVT verified with ultrasound. Ischemic stroke is defined as ischemic stroke verified by computer tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding events</measure>
    <time_frame>28 days from ICU-admission</time_frame>
    <description>The event of bleeding will be defined by WHO modified bleeding scale as 1-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days alive from ICU-admission</measure>
    <time_frame>28 days from ICU-admission</time_frame>
    <description>ICU-free days alive during 28 days from ICU-admission. Counts as 0 days if discharged to ward for palliative treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days from ICU-admission</time_frame>
    <description>90-day mortality from admission to ICU.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fibrin-D-dimer levels</measure>
    <time_frame>28 days from ICU-admission</time_frame>
    <description>Median value of Fibrin-D-dimer</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">257</enrollment>
  <condition>Covid19</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>low dose thromboprophylaxis</arm_group_label>
    <description>Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose thromboprophylaxis</arm_group_label>
    <description>Daily dose of &gt;4500 IU but &lt;175 IU/kg of body weight tinzaparin or &gt;5000 IU but &lt;200 IU/kg of body weight dalteparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose thromboprophylaxis</arm_group_label>
    <description>Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose of tinzaparin or dalteparin</intervention_name>
    <description>The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU</description>
    <arm_group_label>high dose thromboprophylaxis</arm_group_label>
    <arm_group_label>low dose thromboprophylaxis</arm_group_label>
    <arm_group_label>medium dose thromboprophylaxis</arm_group_label>
    <other_name>Innohep/Fragmin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort study of the critically ill Covid-19 patients admitted to ICU at Södersjukhuset,&#xD;
        Stockholm from1st of March to 15 of July&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  laboratory confirmed positive test for SARS-CoV-2&#xD;
&#xD;
          -  admitted to ICU because of respiratory failure caused by Covid-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with treatment for thromboembolic complications at arrival to the ICU&#xD;
&#xD;
          -  short ICU length of stay defined as discharged the same date as ICU admission&#xD;
&#xD;
          -  patients without initial thromboprophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Jonmarker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 18, 2020</last_update_submitted>
  <last_update_submitted_qc>October 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Sandra Jonmarker</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD-student</investigator_title>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Critical Care</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

